Comparison of two metabolomics-platforms to discover biomarkers in critically ill patients from serum analysis

被引:0
作者
Fonseca, Tiago A.H. [1 ,2 ,3 ]
Von Rekowski, Cristiana P. [1 ,2 ,3 ]
Araújo, Rúben [1 ,2 ,3 ]
Oliveira, M. Conceição [4 ]
Justino, Gonçalo C. [4 ]
Bento, Luís [5 ,6 ]
Calado, Cecília R.C. [2 ,7 ]
机构
[1] NMS - NOVA Medical School, FCM - Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo Dos Mártires da Pátria 130, Lisbon
[2] ISEL - Instituto Superior de Engenharia de Lisboa, Instituto Politécnico de Lisboa, Rua Conselheiro Emídio Navarro 1, Lisbon
[3] CHRC - Comprehensive Health Research Centre, Universidade NOVA de Lisboa, Lisbon
[4] Centro de Química Estrutural - Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais 1, Lisbon
[5] Intensive Care Department, ULSSJ - Unidade Local de Saúde de São José, Rua José António Serrano, Lisbon
[6] Integrated Pathophysiological Mechanisms, CHRC - Comprehensive Health Research Centre, NMS - NOVA Medical School, FCM - Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo Mártires da Pátria, Lisbon
[7] IBB-Institute for Bioengineering and Biosciences, The Associate Laboratory Institute for Health and Bioeconomy (i4HB), Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, Lisbon
关键词
Fourier transform infrared spectroscopy; Liquid chromatography; Mass spectrometry; Metabolomics;
D O I
10.1016/j.compbiomed.2024.109393
中图分类号
学科分类号
摘要
Serum metabolome analysis is essential for identifying disease biomarkers and predicting patient outcomes in precision medicine. Thus, this study aims to compare Ultra-High Performance Liquid Chromatography-High-Resolution Mass Spectrometry (UHPLC-HRMS) with Fourier Transform Infrared (FTIR) spectroscopy in acquiring the serum metabolome of critically ill patients, associated with invasive mechanical ventilation (IMV), and predicting death. Three groups of 8 patients were considered. Group A did not require IMV and survived hospitalization, while Groups B and C required IMV. Group C patients died a median of 5 days after sample harvest. Good prediction models were achieved when comparing groups A to B and B to C using both platforms’ data, with UHPLC-HRMS showing 8–17 % higher accuracies (≥83 %). However, developing predictive models using metabolite sets was not feasible when comparing unbalanced populations, i.e., Groups A and B combined to Group C. Alternatively, FTIR-spectroscopy enabled the development of a model with 83 % accuracy. Overall, UHPLC-HRMS data yields more robust prediction models when comparing homogenous populations, potentially enhancing understanding of metabolic mechanisms and improving patient therapy adjustments. FTIR-spectroscopy is more suitable for unbalanced populations. Its simplicity, speed, cost-effectiveness, and high-throughput operation make it ideal for large-scale studies and clinical translation in complex populations. © 2024 The Authors
引用
收藏
相关论文
共 110 条
  • [1] Wishart D.S., Metabolomics for investigating physiological and pathophysiological processes, Physiol. Rev., 99, 4, pp. 1819-1875, (2019)
  • [2] Araujo R., Bento L.F.N., Fonseca T.A.H., Von Rekowski C.P., da Cunha B.R., Calado C.R.C., Infection biomarkers based on metabolomics, Metabolites, 12, 2, (2022)
  • [3] Johnson C.H., Gonzalez F.J., Challenges and Opportunities of Metabolomics, (2012)
  • [4] Huang K., Thomas N., Gooley P.R., Armstrong C.W., Systematic review of NMR-based metabolomics practices in human disease research, Metabolites, 12, 10, (2022)
  • [5] Muthubharathi B.C., Gowripriya T., Balamurugan K., Metabolomics: small molecules that matter more, Mol. Omi., 17, 2, pp. 210-229, (2021)
  • [6] Vanden Berghe T., Hoste E., Paving the Way for Precision Medicine v2.0 in Intensive Care by Profiling Necroinflammation in Biofluids, 10, (2019)
  • [7] Powers R., Riekeberg E., New frontiers in metabolomics: from measurement to insight, F1000Research, 6, (2017)
  • [8] Aderemi A.V., Ayeleso A.O., Oyedapo O.O., Mukwevho E., Metabolomics: a scoping review of its role as a tool for disease biomarker discovery in selected non-communicable diseases, Metabolites, 11, 7, (2021)
  • [9] Moco S., Buescher J.M., Metabolomics: going deeper, going broader, going further, Methods Mol. Biol., 2554, pp. 155-178, (2023)
  • [10] LeWitt P.A., Li J., Lu M., Guo L., Auinger P., Metabolomic biomarkers as strong correlates of Parkinson disease progression, Neurology, 88, 9, pp. 862-869, (2017)